Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.39
$0.473.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -96.24% | -14.21% | |||
| Gross Profit | 96.22% | 14.47% | |||
| SG&A Expenses | 111.72% | -750.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 337.90% | -138.53% | |||
| Operating Income | -336.59% | 138.75% | |||
| Income Before Tax | 9.51% | -9.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.51% | -9.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.51% | -9.12% | |||
| EBIT | -336.59% | 138.75% | |||
| EBITDA | -324.34% | 140.88% | |||
| EPS Basic | 9.52% | -9.12% | |||
| Normalized Basic EPS | -314.46% | 146.04% | |||
| EPS Diluted | 9.57% | -9.02% | |||
| Normalized Diluted EPS | -314.46% | 146.04% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||